Unternehmensprofil · Healthcare

Hikma Pharmaceuticals PLC

HIK · LSE
Land / Region
UK
Mitarbeiter
9.500
Buffett Score
52/100
Mittel
Marktkapitalisierung3,27 Mrd. £
Umsatz (TTM)3,42 Mrd. £
EBITDA879 Mio. £
Nettomarge11,32 %
ROE15,41 %
KGV (TTM)11,88
Erwartetes KGV8,42
PEG2,38
EPS0,01 £
Dividendenrendite5,47 %
52-Wochen-Spanne11,35 £ – 17,83 £

Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Geschichte

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Branchenposition

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Noch keine Analysen zu dieser Aktie in Ihrer Sprache.